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Abstract
Hybrid Cyclic/Linear Peptides in a Multi-Component Lipid Structure as a siRNA Delivery
System
by Abdulaziz Alasmari

Delivering siRNA is challenging due to many obstacles, such as extremely short in vivo
half-life, rapid elimination via glomerular filtration, and inability to cross cell membranes due to
the hydrophilic and negatively-charged nature. Thus, a delivery system is needed to deliver the
siRNA into the cells by crossing the negatively-charged phospholipid cell membrane. The goal of
this project was to design hybrid cyclic-linear peptides as siRNA delivery system. We designed
and synthesized hybrid cyclic-linear peptides [R5K]W5, [R6K]W6, and [R5K]W7 containing
positively-charged arginine residues attached to hydrophobic tryptophan chains for more efficient
interaction with siRNA and to improve siRNA internalization into the cell. SYBR Green II dye
exclusion assay showed a high binding affinity of the peptides with siRNA. The delivery of siRNA
into the cells was further enhanced by incorporating hybrid peptides into a multi-component
structure called Peptide/Lipid-Associated Nucleic Acids (PLANAs). The efficiency of PLANA
for delivery of siRNA to human breast cancer cells was studied by using flow cytometry, exhibiting
significantly higher uptake of siRNA with PLANA-containing peptides. The PLANA containing
siRNA exhibited protein silencing more efficiently than that of lipofectamine.
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Introduction

Chapter 1.

1.1. Statement of the Problem
One of the most frequently diagnosed cancers in women is breast cancer and considered
the second cause for cancer-related death [1]. Breast cancer can occur when the cell cycle proteins
are deregulated. RNA interference plays an important role in regulating the gene expression level
within the cells [2]. However, delivering small interfering RNA (siRNA is challenging due to
many obstacles, such as extremely short half-life in vivo, rapid elimination via glomerular
filtration, and inability to cross cell membranes (due to the hydrophilic nature and negative charge
of siRNA molecules). Therefore, an efficient delivery system for siRNA would make the RNA
interference possible as a treatment strategy for cancer. The aim of this project is to deliver siRNA
to human breast cancer cells in order to prevent the overexpressed proteins and to stop the
translation of mRNA to the protein.
The delivery system needs to deliver the negatively-charged siRNA into the cells by
crossing the negatively charged phospholipid cell membrane. Cell-penetrating peptides (CPPs)
can be used as a component in the delivery system since they facilitate penetrating the cell
membrane and the delivery of siRNA [3]. The goal of this project is to design a drug delivery
system in which hybrid peptides can interact with siRNA to form stable particles and internalize
siRNA into the cell. The delivery of siRNA into the cells can be further enhanced by
incorporating hybrid peptides into a multi-component structure called Peptide/Lipid-Associated
Nucleic Acids (PLANAs).
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1.3. Hypothesis and Rationale
We hypothesize that a cell-penetrating peptide can be incorporated into a multi-component
delivery system (containing neutral and cationic lipids) to enhance siRNA delivery to cancer cells.
This nanoparticle can be further decorated with polyethylene glycol (PEG) and a targeting moiety
for effective in vivo siRNA delivery. The rationale of the project is that by incorporation of ahybrid
peptide in the PLANA structure, the efficiency of siRNA cellular delivery will be improved, due
to cellular internalization of the peptide. The objective of this study is to characterize the PLANAs
incorporating hybrid peptides with different chemical structures for siRNA delivery. We will
investigate three different hybrid peptides for this purpose: [R5K]W5, [R6K]W6, and [R5K]W7. The
positive charge of this peptide comes from the arginine amino acid residues in the ring, which is
important for the interaction with negatively-charged siRNA. As a result of this interaction, the
negative charge of siRNA will be neutralized, which will increase the chance of cellular
internalization. Moreover, the interaction with the cell membrane needs to be enhanced, and the
tryptophan side chain is designed to increase the hydrophobicity of the peptide. This project has
three specific aims: 1. Incorporate the hybrid peptides into PLANA; 2. Study and characterize the
interaction of designed PLANA with siRNA; and 3. Determine the efficiency of siRNA delivery
and protein silencing in human breast cancer cells
1.4. Justification and Significance of the Study
RNAi therapy has the potential to be an important treatment strategy for cancer. However,
the cellular delivery of siRNA is the main barrier to achieve this goal. By using the cell-penetrating
peptides incorporated into PLANA structures, this delivery challenge can be overcome. Previous
efforts for delivering siRNA include using of polyplexes, lipoplexes, and liposomes, whereas in
this project the PLANA delivery system adds the advantage of siRNA stability and enhancement
2

of cell internalization through the interaction between hybrid peptides and siRNA and cell
membrane.

1.5. Summary of Results
We found that the hybrid peptide enhanced the performance of the multicomponent
siRNA delivery system. We tested the delivery system for cellular internalization of siRNA, and
it was efficient when compared with the positive control (lipofectamine). Furthermore, the
delivery system was able to silence a targeted protein model indicating the efficiency of the
system in achieving the desired biological activity.
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Chapter 2
Hybrid Cyclic/Linear Peptides in a Multi-Component as a siRNA Delivery System
Abstract
Small interfering RNA is a promising therapeutic agent. However, delivering siRNA is
challenging due to many reasons, such as extremely short in vivo half-life, rapid elimination via
glomerular filtration, and inability to cross cell membranes due to the hydrophilic nature and
negatively-charged molecules. Thus, a delivery system is needed to deliver siRNA into the cells
by crossing the negatively-charged phospholipid cell membrane. The goal of this project was to
design hybrid cyclic-linear peptides as siRNA delivery system. We designed and synthesized
hybrid cyclic-linear peptides [R5K]W5, [R6K]W6, and [R5K]W7 containing positively-charged
arginine residues attached to hydrophobic tryptophan chains for more efficient interaction with
siRNA and to improve siRNA internalization into the cell. SYBR Green II dye exclusion assay
showed a high binding affinity of the peptides with siRNA. The delivery of siRNA into the cells
was further enhanced by incorporating hybrid peptides into a multi-component structure called
Peptide/Lipid-Associated Nucleic Acids (PLANAs). The efficiency of PLANA for delivery of
siRNA to human breast cancer cells was studied by using flow cytometry, exhibiting significantly
higher uptake of siRNA with PLANA containing peptides. The PLANA containing siRNA
exhibited protein silencing more efficiently than that of lipofectamine.
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2.1. Introduction
During the last 20 years, a lot of effort has been made to overcome this challenge mainly
through chemically modifications of single-stranded antisense oligonucleotides by improving
their stability, gaining higher affinity, and reducing toxicity [3]. A new era was started by
discovering the RNA interference therapy, epically when the double-stranded short interfering
RNAs (siRNA) was found to be very effective in silencing their target mRNA more than 100
times than that of single-stranded antisense [4]. siRNA has shown to have therapeutic potential
against cancer and other diseases. siRNA technology works through regulating the sequence of
specific gene silencing in a unique endogenous pathway.
On the other hand, siRNA technology use has some limitations. The fast serum nuclease
degradation of siRNA explains the short half-life that ranges between a few min. to 1 h, which
makes it harder to use it systemically. Thus, siRNA has to be tested before using clinically [5].
Another limitation is low cellular uptake due to the physiochemical properties of siRNA for
instance, negative charge, and the large molecular size [6]. siRNA is large enough when
compared with conventional drugs, which make the cell uptake more challenging [6].
Other limitations include rapid renal clearance, toxicity, poor targetability in which
siRNA might silence different unknown genes other than the specific target gene, and it could
initiate an immune reaction where the innate immunity plays a major role when it is activated for
example, by the nucleic acids of bacteria or viruses [7]. siRNA was also found to trigger some
immune receptors such as protein kinase receptors (PKR) as well as a few other toll-like
receptors (TLR) [8]. Moreover, some studies have showed the relationship between the siRNA
and the activation of the innate immunity, where the interferon expression increase when the
siRNA is introduced [9].
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2.1.1. siRNA Delivery
Due to the physicochemical properties of siRNA, which makes it unstable and degradable
in bloodstream an efficient drug delivery system is needed to ensure the site delivery of siRNA
so it can produce the desired clinical activity. siRNA carriers are the delivery vehicles that
facilitate cellular uptake of gene therapy. The delivery systems of siRNA fall under two main
classes, which are viral and non-viral [10]. Each class has some limitations for example, viral
carriers are associated with higher toxicity when compared to their counterparts, which justifies
the shift toward non-viral vectors for delivering nucleic acids due to their low toxicity [11].
The non-viral delivery systems have some advantages over the viral ones, such as
biodegradability and a positively net charged for instance, cationic lipids, dendrimers, cationic
cell-penetrating peptides, and cationic polymers.

2.1.1.1. Polymers
Recently there is more focus on chemical and structural modifications of siRNA and its
delivery methods to help overcome the structural and biological barriers of it. One of the
chemical modifications that is suggested to overcome the siRNA structural problem is to
increase the molecular weight and charge density of siRNA. In order to increase the molecular
weight, a chemical polymerization can be utilized where a crosslinker with a cleavable disulfide
bond is used to enhance the formation of more stable, higher binding, more targeted delivery of
siRNA [12].
Another modification is using natural polymer and protein-based nanocarriers for siRNA
delivery. Natural polymers have many advantages when used to deliver siRNA, such as safety,
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low toxicity, and low clearance rate because of the steric barrier of protein-based carriers [13].
Specificity and activity of siRNAs can be enhanced by using site-specific modifications, such as
unlocked nucleic acid (UNA), locked nucleic acid (LNA), and 2′-O-methylation (OMe)” [14].
There are two different types of polymers, natural and synthetic. Polysaccharides and
peptides are examples of natural polymers while Polyethylenimine (PEI), Poly-L-lysine (PLL),
Poly-D, L-lactide-co-glycolide (PLGA), Polymethacrylate and Dendrimers are examples of
polymers that were made in labs [15]. Other examples of synthetic polymers are polyethylene
glycol (PEG), dendrimers, and chitosan that are explained below.

2.1.1.1.1 PEGylation
For many years, the surface modification of nanoparticle with PEG was one of the best
options to enhance the efficiency of the siRNA delivery systems. PEGylation has many
limitations and serious challenges such as “lack of functionality, hindered cellular interaction,
and allergic reaction[16] that is why new ideas were introduced in order to overcome the
limitations of PEGylation such as using a low molecular weight, branched polyethyleneimine
(bPEI)–lipid conjugate as a surface modification on liposomal formulations instead of
PEGylation since it offers many advantages for example, higher stability in ion and protein-rich
mediums [16, 9].

2.1.1.1.2. Dendrimers
Dendrimers can be defined as synthetic polymers with spherical hyper-branched
polymers. Dendrimers have been used more often to deliver nucleic acids because of their unique
structural features as they have lots of accessible terminal functional groups, wide range of
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molecular size. Furthermore, their structure enables them to load a larger number of therapeutic
agents to eventually deliver them into cells [17]. Polycationic dendrimers like poly(amidoamine)
(PAMAM) and poly(propylenimine) (PPI) dendrimers are two examples of vehicles that are used
to deliver siRNA because of their positive charge which makes the encapsulation rate much
better because of the negative charge of siRNA which makes the attraction between the nucleic
acids and the dendrimers stronger compared to other delivery systems [18].

2.1.1.1.3. Chitosan
Chitosan is another delivery vehicle that is used to deliver siRNA. Chitosan is a natural
cationic polysaccharide that has many favorable features such as the ability to condensate siRNA
as well as having an efficacious complexation [19] [20]. Beside that Chitosan is resistant to
nuclease, biodegradable, biocompatible and also very useful when used in vivo due to the
mucoadhesive characteristics [21], [22]. On the other hand, Chitosan has some limitations e.g.
low solubility in water at pH values more than 6.5; and it does not have good colloidal stability
in physiological media [23]. In addition to that, Chitosan has poor transfection efficiency and
limited endosomal escape because of the low buffer capacity [24]. In order to solve the stability
and solubility limitations of Chitosan, scientists have suggested a chemical modification to form
Polyethylene glycol (PEG)-grafted chitosan (C PEG) which has better stability and solubility
[25].

2.1.1.1.4. Polyethylenimines
Another improvement that was evaluated to enhance the efficacy of the gene transfection
was through attaching PEI in the C PEG [26]. Polyethylenimines are also, used as a delivery
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system for siRNA, whereas the difference between them and chitosan is that they are
synthetically made and water-soluble cationic polymers. Polyethylenimines can be linear or
branched while their size, molecular weight, and lengths are varied. Polyethylenimine is one of
the best choices when it comes to gene delivery for the following reasons. First, it contains a
large number of amine groups that attract proteins, which prevent the acidification of endosomal
pH. Second, it enhances the osmotic pressure by inducing the influx of chloride into the
compartment [27]. Polyethylenimines deliver siRNA more efficiently as they prevent it from
lysosomal degradation, increase endosomal escape and causing disruption of lysosome [28].

2.1.1.2. Lipid-Based Carriers
Lipid-based carriers are one of the important gene delivery systems that has different
subcategories such as micelles, liposomes, microemulsions and solid lipid nanoparticles [29].
This category is well known and used for siRNA delivery as it has more advantages over the
other delivery systems.

2.1.1.2.1. Liposomes
Liposomes as an example, have been used extensively by researchers as a gene carries
method. Liposomes standout among other lipid-based carriers because it can deliver a higher
number of genes, which means higher gene transfection rate. Moreover, the interaction between
them and the cell membrane is more efficient because of their lipid components. They also have
more clinical applications for in vivo delivery. The structure of liposomes contains two layers
where the inside hydrophilic and the outer layer is hydrophobic. Considering their features such
as biocompatibility, biodegradability as well as structural simplicity that makes them one of most
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popular options to delivery siRNA [30]. Liposomes can be positively charged (cationic),
negatively charged (anionic), or neutral, in which all of them are used to deliver siRNA [31].
Positively-charged (cationic) liposomes can make the cell penetration easier, facilitate
endosomal escape from the compartment, and form a protective layer for the siRNA from the
enzymatic degradation, which ensures the delivery of intact siRNA to the targeted genes. Even
though cationic liposomes are popular as siRNA delivery system, they still have some
drawbacks, e.g. inducing an immune response by activating interferon or as a result of highly
positive charge they can initiate unfavorable reactions with negatively charged serum proteins
[32].
Unlike cationic liposomes, the neutral ones have less toxicity, lower immune responses,
and more time in the bloodstream. On the other side, neutral liposomes have lower transfection
efficiency, which can be explained by lacking the positive charge on the structure [33]. Some
studies demonstrated the improvement of transfection efficiency by incorporating positively
charged lipids into the neutral liposomes formulations, such as 1,2-di-o-octadecenyl-2trimethylammonium propane (DOTMA) and 1,2-dioleoyloxy-3- trimethylammonium propane
(DOTAP) [34].
Another approach used to enhance the neutral liposomes formulation’s efficacy is
including calcium ions in which it helps to form more stable complexation with the negativelycharged siRNA [35]. Liposomes are considered as one of the best delivery systems because of
the amphipathic nature, which facilitates the incorporation of a variety of drugs whether with
hydrophilic and hydrophobic nature. The hydrophobic part of the drug will interact with the
hydrophobic part in the fatty acyl chains while the hydrophilic part will be attached to the
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hydrophilic part of the phospholipid bilayer. Doxil is an anticancer drug with an FDA approval
that includes doxorubicin with liposomes as a delivery system [36].

2.1.1.3. Peptide-Based Delivery System
Peptide -based siRNA delivery system is another tool that has been used to carry DNA
and RNA into cells. Cell-penetrating peptides (CPPs) can penetrate cells to deliver different
macromolecules for instance, oligonucleotides, antibodies, and nanoparticles [37]. siRNA will
form a non- covalent bond with CPP as they have opposite charges and can have electrostatic
interactions [38]. As an advantage of having a non-covalent interaction, lower concentrations of
CPPs and siRNA are required to induce a biological response [39]. Using such lower
concentrations of siRNA will result in having lower toxicity and off-target effects, which will
contribute to better siRNA activity and more prevention form nucleases degradation [40].

2.1.1.4. Multicomponent Carriers
2.1.1.4.1. Stable nucleic acid lipid particle (SNALPS)
Recent delivery method used to deliver siRNA is called stable nucleic acid lipid particle
(SNALPS) which contains different lipids such as neutral lipid, catanionic lipid, cholesterol and
diffusible polyethylene glycol (PEG)-lipid. The size of these particles is around 80 nm and their
net charge should be neutral. The cationic lipid plays an important role in condensing siRNA
when the particles are formed [41]. Another advantage for SNALPS is having the ionizable lipid,
which is positively charged that facilitate the entry of SNALPS into the endosomal membrane by
using the acidic endosomal conditions [42].
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In this study we developed a new delivery system for siRNA delivery using the stable
nucleic acid lipid particle or (SNALPS) and we advanced this system by incorporating cell
penetrating peptides (CCP). We hypothesized that CCP will enhance siRNA encapsulation as a
result of the electrostatic interaction between positively charged CCP and the negatively charged
siRNA. The hybrid peptides exhibit a good binding affinity to siRNA which was measured by
SYBR Green II dye exclusion assay. We called our system peptide/lipid associated nucleic acids
(PLANA). PLANA is a delivery system that is more stable and efficient in delivering siRNA.
PLANA deliver siRNA to a breast cancer cell lines more efficiently compared to Lipofectamine.
Moreover, PLANA showed no cytotoxicity to the breast cancer cell lines and other ono-cancer
cell lines such as lung cell lines. Furthermore, PLANA was effectively used to silence a selected
protein model Kinesin Spindle Protein (MSK1) in MDA-MB-231 triple negative breast cancer
cell line.
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2.2. Experimental Procedures

2.2.1. Materials
We used XBridge BEH130 Preparative C18 and XBridge BEH130 C18 columns from Waters
Corporation (Milford, MA, USA) for HPLC analysis. To purify the peptides the LC-2030C 3D
and LC-20AP HPLC columns from Shimadzu (Columbia, MD, USA) were utilized. Highresolution matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF, GT 0264)
from Bruker Inc. (Bremen, Germany) was used to confirm the molecular weights of the peptides.
Tribute Automatic peptide synthesizer (Protein Technologies, Inc.) For peptides synthesis FmocL-Arg(Pbf)-Wang resin (0.33 mmol/g), and H-Arg(Pbf)-2-chlorotrityl resin (0.57 mmol/g and
0.44 mmol/g), and Fmoc-Arg(Pbf)-OH, Fmoc-Lys(Dde)-OH, Dde-Lys(Boc)-OH, DdeLys(Fmoc)-OH, and Fmoc-Lys(Boc)-OH were used, and were purchased from AAPPTec
(Louisville, KY, USA). Stearic acid, piperdine, N,N-diisopropylethylamine (DIPEA), hydrazine
monohydrate, anisole, thioanisole, dithiothreiitol (DTT), N-methylmorpholine, trifluoroacetic
acid, acetonitrile, dichloromethane, α-cyano-4-hydroxycinnamic acid, and trifluoroethanol (TFE)
were obtained from Sigma-Aldrich (St. Louis, MO, USA). SYBR Green II, LipofectamineTM
2000, and Silencer® Negative Control siRNA (Catalogue number AM4635) were purchased
from Life Technologies (Grand Island, NY, USA). Molecular Biology grade Water, was
purchased from Mediatech, Inc. (RNase-free), Lot#29216004, all the lipids (1,2-dioleoyl-snglycero-3-phosphoethanolamine (DOPE), 1,2-Dioleoyl-3-trimethylammonium propane
(DOTAP), Cholesterol, Phosphatidylcholine, were obtained from Avanti Polar Lipids, Inc.
(Alabaster, AL, USA). For PLANA preparation Avanti Mini Extruder with filter sized 100
nanometers form Avanti Polar Lipids, Inc. (Alabaster, AL, USA) was used. Table 2.1. shows the
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siRNAs used in this study. To check the size and charge of PLANA Malvern Zetasizer (Serial
No. MAL118774). (Westborough, MA), Disposable size cuvette (Cat. # ZEN0040), Disposable
folded capillary cell for zeta potential (Cat. # DTS1070), was utilized. For staining the cell nuclei
VECTASHIELD VIBRANCE with DAPI from Vector Laboratories (Burlingame, CA, USA)
was used. As a dialysis bag Biotech CE tubing (Cat. #131342) was utilized. From Bio-Rad
(Hercules, CA, USA) Western blot materials was purchased including 10% Mini-PROTEAN®
TGX Stain-FreeTM Protein Gels, Mini-PROTEAN® Tetra Electrode Assembly, ClarityTM
Western ECL Substrate, Trans-blot® TurboTM Cassettes, Trans-Blot® TurboTM Mini PVDF
Transfer Packs, Precision Plus Protein Western C Standards, 10X Tris/Tricine/SDS, Bio-Safe
Coomassie G-250 Stain, Coomassie Brilliant Blue R-250 Destaining Solution, and 10x
Tris/Glycine/SDS). Negative control siRNA labeled with Alexa Fluor 488 (AF488; Catalogue
number 1027292), and the siRNA targeting RPS6KA5 (Catalogue number SI02225433; Sense:
5′-GCCAGUCAUUCGAGAUGAATT-3′; Antisense: 5′-UUCAUCUCGAAUGACUGGCTT-3′)
were obtained from Qiagen (Valencia, CA, USA). RPS6KA5 Human MSK1 (C27B2) rabbit
monoclonal Antibody (Catalogue number 3489S), anti-rabbit IgG, HRP-linked secondary
antibody (7074S), and human GAPDH (D4C6R) Mouse monoclonal antibody (Catalogue
number 97166S) were purchased form Cell signaling Inc. (Danvers, MA, USA). Anti-mouse
polyclonal secondary antibody (Goat Anti-Mouse IgG HRP-linked; Catalogue number HAF007)
was provided by R&D Systems (Minneapolis, MN, USA). Cell Counting 8 (CCK8) KIT was
obtained from Biotool (Houston, TX, USA). Human breast cancer cell line MDA-MB-231, was
obtained from American Type Culture Collection (ATCC; Manassas, VA; Cat. #: HTB-26™).
The cell culture requirements were provided by VWR (Radnor, PA, USA). FACSVERSE Flow
cytometry, was manufactured by BD Biosciences (San Jose, CA).
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2.2.2. Methods
2.2.2.1. Synthesis of Hybrid Cyclic-Linear Peptides [R5K]W5, [R5K]W6, and [R5K]W7. The
synthesis of hybrid cyclic-linear peptides, [R5K]W5 and [R5K]W6 was accomplished according to
the previously reported procedure [41]. In brief, for the synthesis of [R5K]W7, building block
amino acids, Fmoc-Arg(Pbf)-OH, Fmoc-Trp(Boc)-OH, and Dde-Lys(Fmoc)-OH were used as
building block amino acids in the synthesis. The appropriate resin, H-Arg(Pbf)-2-chlorotrityl (0.44
meq/g, 905 mg), was swelled in 10 mLDMF under dry nitrogen for 15 min. three times. The
solvent was filtered off. The next Fmoc protected amino acid (3 equiv.) was coupled to the Nterminal

in

the

presence

of

2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium

hexaﬂuorophosphate (HBTU) (3 equiv.) and N,N-diisopropylethylamine (DIPEA) (6 equiv.) in
DMF by agitating under dry nitrogen for 1.5 h. The reaction solution was filtered off after the
completion of the coupling. The resin was washed with N,N-dimethylformamide (DMF, 15 mL, 2
× 5 min.). Fmoc deprotection was performed by using piperidine in DMF (20% v/v, 10 mL, 2 ×
15 min.). The reaction solution was filtered off, and the resin was washed with DMF (15 mL, 2 ×
5 min). The subsequent amino acids were coupled and deprotected in a similar manner. After
conjugation of lysine residue containing the protected amino group with Dde, the Fmoc of the side
chain protecting group of lysine was removed in the presence of piperidine in DMF (20% v/v).
Coupling of Fmoc-Trp(Boc)-OH on the side chain of lysine was continued. After Fmoc
deprotection on the last amino acid, the free amino group was capped in the presence of acetic
anhydride (3 equiv.) and DIPEA (6 equiv.). The Dde group of lysine residue was removed in the
presence of hydrazine in DMF (2% v/v). The resin was washed with DMF (15 mL, 2 × 5 min) and
methanol (15 mL, 5 min). The resin was dried under vacuum for 4 h. The resin cleavage cocktail,
dichloromethane:trifluoroethanol:acetic acid (DCM:TFE:AcOH; 35 mL:10 mL:5 mL) was freshly
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prepared. The cleavage cocktail was added to the resin, and the solution was mixed for 3 h. The
filtrate was evaporated under low pressure. Hexane (2 × 20 mL) and DCM (2 ×15 mL) were added
to the residue to remove the acetic acid from the mixture. The crude material was solidified as a
white solid. The crude peptide was dried under vacuum overnight.
After the formation of the linear peptides was confirmed by MALDI mass spectroscopy,
the crude protected peptides were used for the cyclization reaction. Anhydrous DMF (100 mL),
anhydrous DCM (50 mL), N,N′-diisopropylcarbodiimide (DIC, 0.3 mmol, 188 µL) and 1hydroxy-7-azabenzotriazole (HOAt, 0.3 mmol, 122.5 mg) were added to the crude unprotected
linear peptide for cyclization. The cyclization occurred between the free COOH side in arginine
and free NH2 side in lysine. The solution was stirred under dry nitrogen overnight. After the
formation of a cyclic peptide was confirmed by MALDI analysis, the solvents were removed
under reduced pressure. The crude peptide was dried overnight. The cleavage cocktail (TFA,
anisole, thioanisole, 9:1:2 v/v/v and 50 mg of dithiothreitol (DTT), 20 mL total volume) was
added to the crude product. The mixture was stirred at room temperature for 4 h. The crude
peptide was precipitated in cold diethyl ether and centrifuged. Final compounds were purified by
a reversed-phase HPLC LC-20AP pump (Shimadzu Corp., Kyoto, Japan) using a gradient
system of acetonitrile and water and a reversed-phase preparative column (XBridge BEH130
Prep C18; 19 × 250 mm, 10 μm particle size, Waters Corp., Milford, MA, USA). The structure
of the compound was confirmed by high-resolution MALDI-TOF mass spectroscopy (GT 0264;
Bruker Inc., Billerica, MA, USA).”

MALDI-TOF (m/z): [R5K]W7: C115H149N36O14 calculated: 2253.2027, found: 2255.7740 [M+
2H]+. The information for [R5K]W5 and [R6K]W6 have been previously reported [3].
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2.2.2.2. PLANA structural design and preparation
A total of 15 formulations will be prepared (Table 2.1.) where each peptide has 5 formulations.
According to the molar fractions of the PLANA components the needed amount of the selected
peptides, [R5K]W5, [R6K]W6, and [R5K]W7) where mixed with DOTAP, DOPE, cholesterol, and
phosphatidylcholine in aqueous: ethanol ratio 3:1. After the formation of the solutions the Mini
Extruder with 100 nm filter (Alabaster, Alabama) was used to form PLANA by passing the
solution through it 50 times to maintain nanoparticles with 100 nm.

Table 2.1. PLANA contents (all compositions are represented as molar fractions)
Formulation Name
Total Lipid Ratios (DOTAP,
Peptide ratio
DOPE, Cholesterol, and
Phosphatidylcholine)
LANA

0.25-0.25-0.25-0.25

0

PLANA A

0.243-0.25-0.25-0.25

0.00625

PLANA B

0-0.3195-0. 0.3195-0. 0.3195

0.0425

PLANA C

0-0.4575-0.3195-0.5102-

0.0425

PLANA D

0-0.5102-0.1278-0.2556-

0.0425

Table 2.1. PLANA componants
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2.2.2.3. Size and zeta potential measurements

Once the PLANA were prepared as described above the size and ʓ-potential of the nanoparticles
were checked using a Malvern Nano ZS Zetasizer (Westborough, MA). 70 µL of PLANAs was
added to a disposable cuvette (Cat. # ZEN0040) at 25 °C to measure the size of the
nanoparticles. For the measurements of zeta potential 750 µL of PLANAs was added to a
disposable folded capillary cell (Cat. # DTS1070) at 25°C and overall surface charge was
recorded.
2.2.2.4. Encapsulation Efficiency-Peptide incorporation.
To prepare the SDS gel, two 50 ml tubes was used as 15% separating gel and 5% Stacking gel.
In the separating gel tube 4.6 ml deionized water, 10 ml of 30% acrylamide/Bis, 5 ml of Tris, PH
8.8, 0.2 ml of 10% SDS, 0.2 ml of 10% ammonium persulfate and lastly 16 ul of TEMED PH 8.9
were added. The content of the separating gel tube was mixed using the pipette, and transferred
between the glass plates in casting chamber to about ¾ inch below the short plate. To straighten
the level of the gel and remove unwanted air bubbles that may be occur an absolute ethyl alcohol
was added on top of the gel prior to polymerization. Once the gel polymerized the absolute ethyl
alcohol was removed using the Kim wipes. In the Stacking gel tube 2.1 ml deionized water, 5 ml
of 30% acrylamide/Bis, 0.380 ml of Tris, PH 8.8, 0.03 ml of 10% SDS, 0.03 ml of 10%
ammonium persulfate and 16 ul of TEMED, PH 8.9 were added. The content of the Stacking gel
tube was mixed using the pipette and transferred between the glass plates in casting chamber.
Once the stacking gel added the well forming comb will be inserted into the opening between the
glass plates. When the stacking gel polymerized the comb can be removed gently. After
preparing PLANA as described in (PLANA structural design and preparation) method 14 µL of
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PLANA along with three different amounts of free peptide (0.5 µg, 1 µg, and 5 µg) were run on
the 16% polyacrylamide gel for 90 min. 1X Tris/Tricine/SDS (Cat. #1610744, Bio-Rad Hercules,
California) as running buffer was used. The Bio-Safe Coomassie G-250 Stain (Cat. #161-0786,
Bio-Rad Hercules, California) was used to stain the gel for 1 h followed by the Coomassie
Brilliant Blue R-250 Destaining Solution (Cat. #1610438) for de-stain the gel for 1 h. The
solution was changed after 30 min. The Bio-Rad imager (Universal Hood III) was used to image
the bands.
2.2.2.5. siRNA Release rate method
The siRNA release was measured using Spectro fluorometry. Different concentrations of siRNA
30 nM to 0 nM was made by mixing siRNA, 1M saline, and water to obtain a standard curve.
200 µL of SYBR Green Dye II was added to the samples in 96 well BD FluoroBlok MW Insert
and the SpectraMax M5 UV VIZ Plate Reader was utilized to read the fluorescence. PLANA
was prepared as described in (PLANA structural design and preparation) method and 1 mL of it
was added into a 20 kDa MW cutoff CE tubing dialysis bag (Cat. #131342). The dialysis bag
was place in 30 mL DI water and samples of 250 µL were collected from the receiving phase at
different time-points (30 min, 2h, 4h, 24h, 48h, and 72h.). 200 µL of SYBR Green Dye II was
added to the collected samples in 96 well BD FluoroBlok MW Insert and the the SpectraMax M5
UV VIZ Plate Reader was used to read the fluorescence.

2.2.2.6. Cell Lines and Cytotoxicity Method

For this study Human breast cancer cell line MDA-MB-231 from American Type Culture
Collection (ATCC; Manassas, VA; Cat. #: HTB-26™) was used. The cells was incubated at 37
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°C and 5% CO2 using Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) FBS,
100 µg/mL streptomycin, and 100U/mL penicillin. Other human cell lines were included in this
study such as Human MRC-5 lung fibroblast cells (ATCC® CCL-171™), H9C2 human
myocardium cells (ATCC® CRL-1446™), PSC human epidermal keratinocytes (HEKa)
(ATCC® PCS-200-011™), and HepaRGTM human hepatocytes (ThermoFisher Scientific;
HPRGC10) were maintained and subcultured as recommended by the manufacturer.
A 96-well plate was used to seed MDA-MB-231 cells and were treated once 80% confluency
was reached. The treatment was in triplicate with: PLANAs equivalent to 25nM, 50nM, 75nM,
and 100nM, no treatment (only Normal saline) or PLANAs with no siRNA. Treated cells were
incubated at 37 °C for 48 h. after incubation 10 uL of CCK solution (Cat. # B34304) was added
to each well and incubated for 1 h at 37 °C. Once the incubation was done SpectraMax M5 UV
VIZ Plate Reader was used to read the absorbance at 450 n, where, the percentage of viable cells
is normalized based on cells treated with normal saline.
2.2.2.7. Cell Uptake Method
The MDA-MB-231 breast cancer cells were seeded in 24 well plate (Cat. # 10062-896) and
once 80% confluency is reached the cells were treated in triplicate with one of the following
treatments: no treatment (Normal saline), AF488-siRNA/peptide complex, AF488-labeled
siRNA, AF488-siRNA/peptide/DOPE complex, one of the five different PLANAs or
LipofectamineTM 2000 (as positive control)/AF488-labeled siRNA. Lipofectamine TM and
siRNA was diluted and mixed in FBS-and antibiotic-free OPTIMEM and the culture media was
removed while the siRNA complexes were added to the wells in OPTIMEM. Cells were
Incubated for 6 h at 37 ºC and then, complexes were removed after the incubation. The cell
culture medium was added and cells Incubated for 24h at 37 ºC. After 24 h incubation cells were
20

detached using 0.05% trypsin and fixed using 3.7% formaldehyde in 1X PBS. Fixed cells were
transferred to 3 mL flow cytometry tubes. FACSVERSE Flow cytometry was utilized to read
fluorescent-labeled siRNA signal using the fluorescein isothiocyanate (FITC) channel. After the
analysis of each study group the signal gated with NT cells was used to evaluate the percentage
of cells with fluorescence signal.

2.2.2.2.8. Confocal Microscopy method
MDA-MB-231 cells were used to for confocal Microscopy images to track down siRNA inside
cells. Cells were treated with one of the formulations based on the cellular uptake study where
the best formulations were used. The treatment groups used: LANA, PLANA C or PLANA D,
LANA without siRNA or AF488-siRNA. A sterilized cover slips were placed at the bottom of 6well plate and cells were exposed to 10% FBS in DMEM and incubated for 30 min at 37 °. The
FBS was removed after the incubation where the cells were seeded on the surface of the cover
slip. Cells were treated with different study groups and incubated for 24h at 37°C and 5% CO2.
After incubation period the cells were washed with 1 X PBS three times and fixed using (3.7%
formaldehyde in 1X PBS) for 10 min. Fixed cells were raised 3 times in 1 X PBS for 5 min and
the cell membrane was stained using Texas Red Phalloidin solution (40 uL and 10 mg BSA in 10
mL of 1X PBS). After staining cells were incubated for 1h at room temperature and washed 3
times with 1 X PBS for 5 min. One drop of DAPI was added on the slide to stain the nucleus
then the coverslips were placed facing down and was stored away from light for overnight. For
Imaging Nikon A1R high definition resonant scanning confocal microscope and a NIS-Elements
software (AR 4.30.02, 64bit) were used.
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2.2.2.2.9. Silencing method
For this study RPS6KA5 (also known as MSK1) was targeted as a protein model to evaluate
silencing efficiency of PLANA. MDA-MB-231 breast cancer cells were seeded in 6 well plate
where 50% confluency was obtained before the treatment. The treatment groups were: no
treatment, siRNA targeting RPS6KA5 delivered by LipofectamineTM 2000, or PLANA D
formulations. After the treatment cells were incubated for 48h at 37 ºC and 5% CO2.
After incubation for 48h media was removed and cells were washed with 1ml HBSS. 400 ul
0.05% trypsin were added to cells and incubated for 1 min to 2 min at 37 ºC for cells detachment.
Trypsin was deactivated with 2 mL of DMEM low glucose for each well. A 15 ml conical tube
was used for each study group and centrifuged at 600 rpm for 5 min. After centrifugation
supernatant was removed using pasture pipette and vacuum without touching the pellet. 1mL of
1X PBS was added to the pellet and pipette was used for resuspension. Cells were transferred to
1.5 ml Eppendorf tubes and Centrifuged at 3400 rpm for 5 min.The supernatant was removed
and 1X Ripa buffer + inhibitor (10ul protease & phosphatase inhibitor for each1 ml 1X Ripa
buffer) was added to the pellet and pipetted up and down. For 5 min All tubes were kept on ice
and Sonicated for 2 min. After the tubes were vortexed they were kept on ice for 1 h with vortex
every 15 min. all the tubes were centrifuged at the highest speed for 15 min at 4 ºC. Supernatant
that contained the protein was collected in a new 1.5 mL Eppendorf tube and the pellet was
removed. After collecting the protein, 3 ul of the protein sample was added to57 µL 1X PBS. A
96-well plate was used where 25 uL of each sample was added using 2 wells for each sample. A
standard curve was obtained according to manufacturer’s instructions and 25 uL of each standard
concentration was added to the same 96-well plate in triplicate. 200 uL of reagents A and B were
added to each well, and the plate was placed on a shaker for 30 seconds. for 30 min the plate was
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centrifuged at 1500 rpm for 2 min and incubated at 37 ºC. Using a spectrophotometer, the
samples were then analyzed at 562 nm. 10 µg of the extracted protein for each study group was
added to a 1.5 mL Eppendorf tube with enough 1X PBS to reach 25 µL.
25 µL dye was added to each sample. After that, samples were vortexed and centrifuged at the
highest speed for 1 min then incubated at 95ºC for 5 min. samples were one more time and
placed on ice. On a Mini-Protean TGX 10% gel samples were loaded and run at 100 V and 75
mA for about 1 h. using a BioRad TransBlot Turbo Transfer System at 25 V and 1 A for 45 min
the protein was transferred to a membrane. The membrane was washed in 1X TBS for 5 min.
after that, blocking took place by adding 1 g BSA in 20 mL TBST to the membrane for 1 h at
room temperature. Then, in 3% BSA in TBST for overnight, the primary antibody (1:1000) was
added. In the next day, the membrane was washed for 5 min 4 times in TBST. After that, the
ECL kit was prepared to detect the blots where, the ChemiDoc imager (Bio-Rad) was used. For
visualizing GAPDH as the endogenous gene using primary antibody (Cat. #_97166S_) the same
procedure was followed.

2.3.

Results and discussion

2.3.1. Chemistry
In this study, we synthesized three different hybrid cyclic-linear peptide, [R5K]W5, [R5K]W6, and
[R5K]W7 (Figure 2.1). The synthesis of hybrid cyclic-linear peptides, [R5K]W5 and [R5K]W6 was
accomplished according to the previously reported procedure [3]. As a representative example, the
synthesis of [R5K]W7 is shown in Scheme 2.1. Building block amino acids, Fmoc-Arg(Pbf)-OH,
Fmoc-Trp(Boc)-OH, and Dde-Lys(Fmoc)-OH, were assembled on H-Arg(Pbf)-2-chlorotrityl
resin. After conjugation of lysine residue containing Dde, the Fmoc of the lysine was removed in
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the presence of piperidine in DMF (20% v/v). The peptide synthesis was continued by the coupling
of Fmoc-Trp(Boc)-OH on the side chain of lysine. After Fmoc deprotection on the last amino acid
in the peptide chain, the free amino group was capped in the presence of acetic anhydride (3 equiv.)
and DIPEA (6 equiv.). The removal of Dde group of lysine residue was accomplished in the
presence of hydrazine in DMF (2% v/v). After washing, the resin cleavage was accomplished in
the presence of dichloromethane:trifluoroethanol:acetic acid (DCM:TFE:AcOH). The cyclization
was accomplished in the presence of N,N′-diisopropylcarbodiimide (DIC) and 1-hydroxy-7azabenzotriazole (HOAt) in anhydrous DMF and dichloromethane (DCM). The final cleavage in
the presence of TFA, anisole, and thioansiole afforded the crude peptides that were purified by
HPLC.

Figure 2.1. Chemical sructures of hybrid cyclic/linear peptides.
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Scheme 2.1. Synthesis of hybrid cyclic-linear peptide [R5K]W7.

The selected hybrid peptides used for this study contained positively-charged arginine
and tryptophan that forms the hydrophobic tail. The purpose of having the positively charged
rings along with hydrophobic chain was to enhance the interaction with negatively charged
phosphate and the hydrophobic groups in the cellular phospholipid bilayer, which facilitate the
cell penetration and siRNA delivery. We designed three different hybrid peptides (Figure 2.1), in
which the difference between them was the number of arginine residues and the length of the
hydrophobic chain to compare their ability as a part of the siRNA delivery system.

2.3.2. Formulation and siRNA complexation
For this study, we prepared five different formulations for each peptide with different
ratios of peptides and lipids (Table 2.1) to form Peptide/Lipid-Associated Nucleic Acids
(PLANA) as a delivery system for siRNA.
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2.3.3. Size and electrical charge of PLANA
The size and overall surface charge of the PLANA are two important factors when it
comes to the in vitro and in vivo efficacy of such siRNA delivery system. It is critical for this
study to measure the size of the nanoparticles (PLANA) in order to make sure the cellular
delivery is facilitated by maintaining the size of (PLANA) in the range of 120–80 nm.
A dynamic light scattering (Malvern Zetasizer) at room temprture (25°C) was utlized to
determine the size and zeta potential of PLANA. When the PLANA was prepared as discribed in
methods section the size where measured immeaditly. For most of the formulations at time zero
the size was around 120 nm which can be explained by using the Avanti Mini Extruder with
filter sized 100 nm where, the nanoparticles were passed 50 times through the filter. After 72 h in
the dialysis bag, the size of the PLANA was measured again. A noticeable decline in the size of
the formulations was recorded which was a general trend followed by all 15 formulations.
Moreover, the size of PLANA was ranged from 125nm to 80nm. Furthermore, the size of
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PLANA-D for [R6K]W6 (Figure 2.2.) was decreased from 100nm to 80nm and the reduction in
the size most likely because of the partial dissociations over time.
Figure 2.2 represents the PLANA size at time zero, which means right after making the
formulations and passing them 50 times through Avanti Mini Extruder with filter sized 100 nm
to maintain the size of the nanoparticles. Also, the Figure shows PLANA size after 72 h inside
the dialysis bag where the samples recollected from the dialysis bag and their size was checked
using the Malvern Zetasizer. For each peptide, there was 5 different formulations and for each
formulation, the size was measured in triplicate for each formulation at time zero and at time 72
h. the blue coulmns represents the size of the nano particles at time zero while the gray columns
shows the size of the nanoparticles at time 72 h. The bars and error bars represent the mean and
standard deviation values (n = 3), respectively.
Figure 2.2. Size of different PLANA
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As the size of the PLANA is crucial, the surface charge of the PLANA is an important
factor and plays a major role in this study. In order to obtain a sufficient data regarding the zeta
potential of the formulations, the Malvern Zetasizer was used to read the charge of the PLANA.
Moreover, a general trend was obtined after looking at the results where the charge of the
PLANA increased after sitting in the dialysis bag for 72 h. A higher positive charge was noticed
for LANA and PLANA-A of each peptide in compared to the rest of the formulations. LANA
and PLANA-A has cationic Lipid (DOTAP) in the formulation, unlike the rest of the
formulations, which explains the higher positive charge on the surface of PLANA. Moreover, a
significant increase in the surface charge of the formulations after 72 h (Figure 2.3) in the
dialysis bag, was found which can be explained by the dissociation of the PLANA therefore,
more positive charge is associated with unfolded structure of the dissociated PLANA.
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Figure 2.3. a similar method of the size was used with zeta potential, where the zeta potentialof
each formulation was checked twice one at time zero, which is represented with blue color and
one at time 72 h (Figure 2.3), which is shown in the gray color. A total of 15 formulations was
measured. The bars and error bars represent the mean and standard deviation values (n = 3),
respectively.
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Figure 2.3. Zeta Potential of different PLANA

2.3.4. Binding Affinity
The binding affinity for the three hybrid peptides to scrambled siRNA was determined
using SYBR Green II dye exclusion assay. For this experiment different N/P ratios (0 0, 0.05,
0.1, 0.2, 0.5, 1, 2, 4, 6, 8, 10, 20, 40) were used. N/P ratio is the # of N * # of moles of peptide/
#of P * # of moles of siRNA. That was applied for each peptide then, by adding SYBR Green II
dye to the formulations and reading the fluorescent signal at excitation λ = 485 nm and emission
λ =527 nm using SpectraMax, M5 the binding affinity for each peptide to the siRNA was
evaluated using BR50. BR50 = N/P ratio required for 50% binding. After calculating the BR50
for all of the three hybrid peptides, it was found that [R5K]W7 has 5.7 BR50, [R6K]W6 has 6.9
BR50, and [R5K]W5 has 8.3 BR5 Figure 2.4. Among the three hybrid peptides [R5K]W7 was the
one with the highest binding affinity to siRNA while [R5K]W5 was the one with the lowest
binding affinity to siRNA. The results can be explained by the hydrophobicity of the peptides
where the [R5K]W7 has the longest hydrophobic tail so it has the highest affinity to bind with
siRNA. second, was [R6K]W6 and the lowest one was [R5K]W5.
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Figure 2.4. the hybrid peptide’s affinity of binding with siRNA was evaluated using SYBR
Green II dye exclusion assay where, different N/P ratios (0 0, 0.05, 0.1, 0.2, 0.5, 1, 2, 4, 6, 8, 10,
20, 40) was used to measure the N/P ratio required for 50% binding.

[R5K]W7

[R5K]W5

[R6K]W6

Figure 2.5. represent the bands of the PLANA-B of each peptide in comparison with free
peptide loaded in amounts equivalent to 10%, 20%, and 100% of the peptide.
2.3.5. Peptide incorporation
In this project the hybrid peptides were used to enhance the siRNA delivery of the multicomponent lipid structure. Therefore, incorporating the peptides into a multi-component lipid
structure was very important to be confirmed. For this experiment, formulation A or PLANA-A
for all the three hybrid peptides were used to show the efficiency of the incorporation method by
comparing them to three different concentrations (100%, 20%, 10%) of the free peptide. The gel
electrophoresis showed the difference in the particle size of the PLANA-A compared to the free
peptides where the PLANA-A traveled slower in the gel while the free peptides traveled faster
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(Figure2.5.). The difference in the molecular weight between the free peptides and PLANA
proves that PLANA successfully interacted with the hybrid peptides and no bands at the level of
the free peptide’s bands were detected.

2.3.6. Peptide/siRNA release rate
The release rate of the peptide over time up to 48 h was investigated using the dialysis
bag experiment. In this study, the three hybrid peptides were incorporated into the PLANA-A
then it was loaded into the dialysis bag 20 kDa. Samples were collected from the receiving phase
at different time points 30 min, 2 h, 4 h, 24 h, and 48 h. After that, the samples were loaded into
the gel electrophoresis against three different concentration of free peptides (100%, 20% and
10%), and the band intensity was measured using Bio-Rad imager (Figure 2.6.). The results
suggest a steady release of the peptides over time, which is required in order to have an efficient
delivery system. Moreover, we can conclude from the constant rate of the peptide release that the
PLANA delivery system is not dissociating so early which is an advantage for a delivery system
at the same time after the appropriate time the PLANA is releasing its content for example
siRNA when it starts to dissociate.

Figure 2.6. in this study PLANA-A was prepared for all three peptides and added to a dialysis
bag to measure the peptides released out of the formulation over 48h. the upper gel shows
[R6K]W6 containing PLANA-A and the lower one shows [R5K]W7 containing PLANA-A.
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Another important test for PLANA was evaluating the rate of the siRNA release from the
PLANA formulation. PLANA formulations were tested in this experiment using the dialysis bag
20kDa to calculate the percentage of siRNA release over time. To perform such studies, the
formulations were prepared as described in the method section. After that, the size and zeta
potential of the PLANA were measured before proceeding with siRNA release experiment.
Furthermore, each of the formulations were added to dialysis bag with 20 kDa and immersed in
30 mL of purified water as receiving phase and start stirring for the next 72 h. Samples will be
collected at fixed time-points for (30 min, 2 h, 4 h, 24 h, 48 h, and 72h) to be analysed for the
free siRNA content.
As shown in (Figure 2.7.) the siRNA release rate was obtained for the different
formulations compared to LANA and free siRNA. ⁓77% of free siRNA was measured at 24h
and about 97% was released at 72h. for the LANA which has no peptide it showed 37 and 72%
release at 24 h and 72 h respectively. PLANA D formulations found to have a higher release rate
at 72h (31%, 32%, and 39% [R6K]W6, [R5K]W5, and [R5K]W7, respectively). On the other hand,
PLANA C formulations showed some of the slowest release rates, with ⁓11%, 13%, and ⁓20%
release at 72 h in general, PLANA formulations except LANA controlled the release of siRNA
over time.
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Figure 2.7. in this study the free siRNA released in the receiving phase was quantified for
different PLANA formulations compared to free siRNA. Free siRNA released from the dialysis
bag much faster than other PLANAs. LANA which has no peptide was released faster than other
PLANAs with hybrid peptides incorporated. The error bars standard deviation values (n = 3).
2.3.7. Cytotoxicity
After the successful siRNA release investigations of PLANA formulations, it was important to
check the cytotoxicity of the delivery system to ensure that it is not toxic and non-harmful to the
cells. The cell viability assay was utilized where all the formulations for each hybrid peptide with
five different siRNA concentrations (no siRNA, 25 nM, 50 nM, 75 nM, and 100 nM) were
evaluated using Human MRC-5 lung fibroblast cells (ATCC® CCL-171™), H9C2 human
myocardium cells (ATCC® CRL-1446™), PSC human epidermal keratinocytes (HEKa)
(ATCC® PCS-200-011™), and HepaRGTM human hepatocytes (ThermoFisher Scientific;
HPRGC10) and MDA-MB-231. (Figure 2.8.) represent the cell viability test for [R5K]W5 where
the first and second formulations with DOTAP as cationic lipid showed toxicity while the last
three formulations showed no significant toxicity. [R5K]W5 containing LANA with no peptide at
concentration of 100nM has (⁓ 50 % viability). Figure 2.9. shows the cytotoxicity results for
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[R6K]W6 formulations where, toxicity for the first and second formulations was recorded.
[R6K]W6 containing PLANA-A at concentration of 100nM has (⁓ 60 % viability). On the other
hand, the last three formulations showed no significant toxicity. Figure 2.10 shows the cell
viability results for [R5K]W7 where the first two formulations showed higher toxicity to the cells
when compared to the other two peptides e.g. [R5K]W7-containing PLANA-A formulation at
concentration 100 nM siRNA (⁓ 31% viability). However, the last three formulations of the
[R5K]W7 suggest no significant toxicity to the cells. We noticed when the formulations contain
DOTAP, the toxicity increases such as LANA and PLANA- A for each peptide. Moreover, the
toxicity is associating with more positive charge coming from the catanionic lipid (DOTAP). On
the other hand, when the formulations have no DOTAP e.g. formulation C, D, and E show lower
toxicity when incubated with cells.

Figure 2.8. Four non-cancerous healthy human cell lines: MRC-5 human lung cell line, H9C2
human myocardium cell line, HepaRGTM human hepatocytes, and PSC human epidermal
keratinocytes (HEKa) were used to evaluate the cytotoxicity of PLANA at two different siRNA
concentration (50 and 100 nM). The incubation time was 48h. The bars and error bars represent
the mean and standard deviation values (n = 3), respectively.
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Figure 2.9. The cytotoxicity of [R5K]W5 formulations at different siRNA concentrations (no
siRNA, 25 nM, 50 nM, 75 nM, and 100 nM) were evaluated using MDA-MB0-231 breast cancer
cell lines. The incubation time was 48h. The bars and error bars represent the mean and standard
deviation values (n = 3), respectively.
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Figure 2.10. The cytotoxicity of [R6K]W6 formulations at different siRNA concentrations (no
siRNA, 25 nM, 50 nM, 75 nM, and 100 nM) were evaluated using MDA-MB0-231 breast cancer
cell lines. The incubation time was 48h. The bars and error bars represent the mean and standard
deviation values (n = 3), respectively.
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Figure 2.11. The cytotoxicity of [R5 K]W7 formulations at different siRNA concentrations (no
siRNA, 25 nM, 50 nM, 75 nM, and 100 nM) were evaluated using MDA-MB0-231 breast cancer
cell lines. The incubation time was 48h. The bars and error bars represent the mean and standard
deviation values (n = 3), respectively
2.3.8. Cellular internalization
Cellular uptake studies of PLANA system to deliver siRNA was performed using FACS
VERSE Flow cytometry in MDA-MB-231 cells. For this experiment, fluorescent-labeled siRNA
was used to read the signal intracellularly. Also, lipofectamine, which is used as a delivery
system for siRNA and is commercially available, was utilized in this study as a positive control.
Figure 2.12. shows the % total of the MDA-MB-231 breast cancer cells positive for siRNA
signal for [R5K]W5 PLANA formulations. PLANA- C and D delivered up to 82%, 88%
respectively, while, Lipofectamine internalization efficiency was comparable to PLANA-D and
E.
Figure 2.13. represents the cellular uptake results for the second cell-penetrating peptide,
which is [R6K]W6. The results suggest comparable delivery efficiency of the fluorescent-labeled
siRNA to the breast cancer cells between lipofectamine and PLANA-C and D. In this study,
lipofectamine delivered more than 80% of the siRNA to the cells, and the PLANA-C and D
delivered up to 81% and 90%, respectively.
The results indicate higher efficiency of the PLANA delivery system in delivering siRNA
to the breast cancer cells. Figure 2.14. shows the results of [R5K]W7 where, the lipofectamine
delivered siRNA to the cancer cells more efficiently compared to PLANA, the lipofectamine
delivered up to 94%, and PLANA-C and delivered up to 58% and 60%, respectively. Also,
using the cell-penetrating peptide with DOPE alone delivered up to 60% of siRNA. The
performance of PLANA depends on the peptide’s chemical properties e.g. the more
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hydrophobicity seems to be not as efficient as the lower hydrophobicity in terms of siRNA
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Figure 2.12. The total % of the cells that internalized siRNA- fluorescence labeled was
determined for [R5K]W5 PLANA with all formulations. The bars and error bars represent the
mean and standard deviation values (n = 3), respectively
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Figure 2.13. The total % of the cells that internalized siRNA- fluorescence labeled was
determined for [R6K]W6 PLANA with all formulations. The bars and error bars represent the
mean and standard deviation values (n = 3), respectively
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Figure 2.14. The total % of the cells that internalized siRNA- fluorescence labeled was
determined for [R5K]W7 PLANA with all formulations. The bars and error bars represent the
mean and standard deviation values (n = 3), respectively
2.3.9. Confocal Microscopy
To confirm the results of cellular uptake studies confocal microscopy was used to
visualize the siRNA inside the cells. PLANA-D for all three peptides was used since it has the
best results in the cellular uptake study among the other formulations. We found that siRNA by
itself has no florescent (Figure 2.15), which was expected because of the poor cellular
internalization ability. On the other hand, when using lipofectamine, we do see fluorescent
(Figure 2.15), which means the siRNA was able to internalize the cells. Treatment groups with
PLANA for all three peptides showed a clear fluorescent (Figures 2.16. and 2.17), which means
the PLANA-D was able to deliver siRNA efficiently to the MDA-MB-231 cells.
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Figure 2.15. AF 488-labeled siRNA and Lipofectamine containing AF 488-labeled siRNA are
shown where, (green channel), using Texas Red Phalloidin and DAPI to stain cell membrane and
nuclei (red and blue channels), respectively.

Figure 2.16. [R5K]W5 containing PLANA-D and [R6K]W6 containing PLANA-D, are shown
where, (green channel), using Texas Red Phalloidin and DAPI to stain cell membrane and nuclei
(red and blue channels), respectively.
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Figure 2.17. [R5K]W7 containing PLANA-D is shown where, (green channel), using Texas Red
Phalloidin and DAPI to stain cell membrane and nuclei (red and blue channels), respectively.

2.3.10. Protein silencing
In this study, we targeted two models of protein tyrosine-protein kinase Src and kinase
RPS6KA5 (MSK1), to demonstrate the efficiency of PLANA to deliver siRNA. Lipofectamine
was used as a positive control, and GAPDH was used as an endogenous protein to normalize the
band intensities. Two PLANA-D for two peptides [R5K]W5 and [R6K]W6 were tested as well.
We noticed a protein silencing for both PLANAs (Figure 2.18) when compared to no treatment
or saline as the negative control, which indicates the ability of PLANA to deliver the targting
siRNA and induce the desired biological response. PLANA-D for [R5K]W5 performed better
than [R6K]W6, in which the silencing was 64% compared to 81% (Figure 2.19).
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Figure 2.18. represents the silencing efficiency of the PLANA delivery system for targeting
siRNA. The [R5K]W5 and [R6K]W6 with PLANA-D were able to silence the targeted protein
models (RPS6KA5 and Src)
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Figure 2.19. shows the RPS6KA5 Expression % after siRNA treatment using PLANA delivery
system.

Figure 2.20. shows the Src Expression % after siRNA treatment using PLANA delivery system.

2.4.

Conclusion
In conclusion, we investigated the ability of hybrid cyclic/linear peptides in a multi-

component as a siRNA delivery system, and we were able to demonstrate the efficiency of this
system to deliver siRNA to the cells. Also, the therapeutic activity of the siRNA was evaluated
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by targeting a specific protein model tyrosine-protein kinase Src and kinase RPS6KA5 (MSK1)
which was targeted for silencing using PLANA delivery system. Moreover, the safety profile of
the delivery system was measured by utilizing cell viability assay where, four different healthy
non-cancer cell lines and MDA-MB-213 breast cancer cell line were used, and the results
suggested that PLANA delivery system has an acceptable safty profile with non-significant level
of toxicity.
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